openPR Logo
Press release

Tapentadol Market Key Players and Competitive Landscape| IPCA Laboratories Ltd., Lupin Laboratories Ltd., Ranbaxy Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd.

08-23-2018 12:36 PM CET | Health & Medicine

Press release from: TMR Research

Tapentadol Market Key Players and Competitive Landscape| IPCA

The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide. Tapentadol is also used for the treatment of moderate to severe acute pain. The potency of this treatment lies somewhere between that of morphine and tramadol. Despite the lower occurrence of side effects, its analgesic efficacy is comparable to that of oxycodone. The treatment is still prescribed to adults as there has been no well-controlled study reported for children. The rising incidence of diabetes is also working in favor of the global market.

Request a sample copy of the Report @ www.tmrresearch.com/sample/sample?flag=B&rep_id=87

However, tapentadol comes with its own set of contraindications, especially in the treatment of people suffering from epilepsy or are susceptible to seizures. People suffering from brain tumor, head injuries, or other conditions should avoid consuming it as it increases intracranial pressure. Its usage is discouraged for people with asthma as it boosts the risk of respiratory depression. Its consumption is also strictly prohibited for patients having biliary tract disease such as both acute and chronic pancreatitis as it may cause spasms of the sphincter of Oddi. Besides this, tapentadol cannot be used for people suffering from severe liver diseases and should be carefully administered to people with the moderate liver disease. Moreover, it is not recommended for treatment of women during and immediately before labor and delivery.

Tapentadol is still in the launch or post-launch phase in several countries across and yet to be commercially introduced in numerous countries. Its marketing is done only in countries where adequate national control steps offering the same control as for schedule I of the United Nations (UN) Single Convention on Narcotic Drugs are applied.

Global Tapentadol Market: Overview

Tapentadol is a dual mode analgesic that performs the actions of being a norepinephrine reuptake inhibitor as well as a mu-opioid receptor antagonist. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol has been recognized as a step three analgesic on the World Health Organization (WHO) pain ladder. Tapentadol is utilized for the treatment of moderate to severe pain for chronic and acute musculoskeletal pain. It is available in the U.S. in extended release formulations under the branded name Nucynta ER from Janssen Pharmaceuticals. Nucynta contains the (R.R.) stereoisomer, which is a weak isomer in terms of opioid activity.

Tapentadol is a newly released drug, being approved by the U.S. Food and Drug Administration (FDA) in 2011, by the Therapeutic Goods Administration (TGA) of Australia in 2010 and by the Medicines and Healthcare products Regulatory Agency (MHRA) of the U.K. in 2011.

Request TOC of the report @ www.tmrresearch.com/sample/sample?flag=T&rep_id=87

Global Tapentadol Market: Product Specifications

Tapentadol is often used to ease pain which cannot be managed with other types of analgesics. Its formulation is provided in 100 mg (red/orange), 75 mg (orange) and 50 mg (yellow) tablets to be used once every five hours as needed to control pain. In addition, tapentadol can be used for controlling the pain of diabetic neuropathy when round-the-clock analgesics are required.

However, tapentadol is known to have adverse side-effects. It may impair cognitive and physical abilities and should not be used when operating heavy machinery, especially during initial treatment. Dizziness, nausea, constipation and central nervous system (CNS) sedation are common side-effects of tapentadol. Its consumption can increase the risk of seizure and should be administered to epileptic patients with extreme caution.

Global Tapentadol Market: Regional Analysis

The growth in the demand for analgesics is expected to increase the overall demand for tapentadol. In addition, the rising demand for over-the-counter painkillers in the emerging economies of Asia Pacific is expected to boost demand for tapentadol. The global tapentadol market, however, is restricted by factors including stringent government regulations, availability of substitutes, and adverse effects of tapentadol could hamper the growth of the market.

North America is the leading market for tapentadol, followed by Europe and Asia Pacific. The demand for tapentadol is exceptionally high in the U.S., owing to a higher percentage of the elderly population, a demographic which forms the leading consumer pool for tapentadol in the world. Asia Pacific is projected to be at the forefront of the global tapentadol in terms of growth. China and India are expected to show a very high rate of increase in the consumers of tapentadol due to their growing population pools and rapid urbanization rates. Taiwan, Honk Kong, Japan, Republic of Korea, Malaysia and Indonesia are other key consumers of tapentadol in Asia Pacific. Increasing consumer awareness, better treatment and an increase in life expectancy is likely to propel future growth.

Read Comprehensive Overview of Report @ www.tmrresearch.com/tapentadol-market

Global Tapentadol Market: Key Players and Competitive Landscape

The market is dominated by large pharmaceutical companies with established brands. Companies are investing in research and development to develop new grades of tapentadol. In addition, companies are using strategic acquisitions and mergers to remain competitive in market and increasing their presence in emerging economies of Asia Pacific and Latin America.

Some of the key players operating in the global tapentadol market so far, have been Johnson & Johnson Pharmaceutical Research & Development, L.L.C., IPCA Laboratories Ltd., Lupin Laboratories Ltd., Ranbaxy Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Cadila Pharmaceuticals Ltd., Tirupati Medicare Ltd, and Manus Aktteva Biopharma LLP.

About Us:
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact Us:
Rohit Bhisey
Head Internet Marketing
Tel: +1-415-520-1050
Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tapentadol Market Key Players and Competitive Landscape| IPCA Laboratories Ltd., Lupin Laboratories Ltd., Ranbaxy Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd. here

News-ID: 1196601 • Views: 279

More Releases from TMR Research

Power Uprates Market Scope and Opportunities Analysis 2017 – 2025 | Lightbridg …
Global Power Uprates Market : Snapshot With escalating population across the world and rapid urbanization in several emerging economies, the demand for power it at an all-time peak. In this scenario, it becomes essential to increase the efficiency of each nuclear power plant. Power uprate is the technique with which not only the maximum heat output can be achieved, it does to in accordance to the plant safety. Get Sample Copy of
IoT Cloud Platform Market Segmentation Detailed Study with Forecast to 2025 | Se …
Global IoT cloud Platform Market: Snapshot The Internet of Things has emerged as a prominent platform for data and information sharing in the IT world. Within a short period of time it has gained popularity and is being used by a large population base. The inter-networking of physical devices, buildings, vehicles, and other items that have been integrated with network connectivity, actuators, software, sensors, and electronics, allowing the objects to accumulate
Smart Advisors Market Latest Trends and Future Growth Study by 2025 | IBM Watson
Global Smart Advisors Market: Snapshot There has been a significant rise in demand for demand for wealth advisory across the globe over the past few years, chiefly owing to the rising wealth of the affluent upper-middle class in emerging economies and the substantial increase in the number of high-net-worth individuals (HNWIs) globally. While financial advisory firms across the globe position themselves to benefit from the vast rise in growth opportunities, a
Cloud Computing in Education Market Share and Growth Factors Impact Analysis 201 …
Global Cloud Computing in Education Market: Snapshot As the rapidly expanding education sector faces sustainability issues and budget restrictions, cloud computing is increasingly being seen as one approach to relieve these pressures. As capacity requirements of an educational institution begin to fluctuate and as new services and applications become available, the association with cloud allows institutions to meet the needs of their constituents in a cost effective and quick manner. As

All 5 Releases


More Releases for Tapentadol

Middle East Tapentadol Market Forecast to 2025
Tapentadol is an opioid analgesic, indicated for severe pain management, on a daily or around the clock need for treatment and long-term opioid treatment, for which alternative treatment options are inadequate. Tapentadol is also indicated for neuropathic pain associated with diabetic peripheral neuropathy. It is widely used for management of acute, chronic, and cancer related pain among patients and is available legally on prescription. Nucynta ER is the first and
Tapentadol Market Furnishes over 2025 - Johnson & Johnson Pharmaceutical Researc …
Global Tapentadol Market: Snapshot The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide. Tapentadol is also used for the treatment of moderate to severe acute pain. The potency of this treatment lies somewhere between that of morphine and tramadol. Despite the lower occurrence of side effects, its analgesic efficacy is
Tapentadol Market Extreme level of competition foreseen 2025
Global Tapentadol Market: Snapshot The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide. Tapentadol is also used for the treatment of moderate to severe acute pain. The potency of this treatment lies somewhere between that of morphine and tramadol. Despite the lower occurrence of side effects, its analgesic efficacy is
Tapentadol Market Latest Growth Segmented 2025
Global Tapentadol Market: Snapshot The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide. Tapentadol is also used for the treatment of moderate to severe acute pain. The potency of this treatment lies somewhere between that of morphine and tramadol. Despite the lower occurrence of side effects, its analgesic efficacy is
Tapentadol Market- Product Specifications and Forecast 2017 - 2025
Global Tapentadol Market: Snapshot The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upswing in the demand for tapentadol worldwide. Tapentadol is also used for the treatment of moderate to severe acute pain. The potency of this treatment lies somewhere between that of morphine and tramadol. Despite the lower occurrence of side effects, its analgesic efficacy is
Tapentadol Market: Set for Rapid Growth and Trend by 2025
Tapentadol is an analgesic with a dual mode of action as a norepinephrine reuptake inhibitor and an agonist of the mu-opioid receptor. Its analgesic properties come into effect within few minutes of oral administration. Tapentadol is a new drug, being approved by the U.S. Food and Drug Administration (FDA) on the twenty sixth of August 2011, by the Therapeutic Goods Administration (TGA) of Australia on the twenty fourth of December